PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20155988-6	2010	The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks.	Ezetimibe	43-52	component of oligomeric golgi complex 2	Homo sapiens	56-91	
20155988-6	2010	The main outcome measure was the effect of ezetimibe on low-density lipoprotein cholesterol (LDL-C) and other lipid levels from baseline to 12 weeks.	Ezetimibe	43-52	component of oligomeric golgi complex 2	Homo sapiens	93-98	
20155988-8	2010	The mean reduction in LDL-C level with ezetimibe monotherapy was significantly greater in patients with impaired LDL-C metabolism, glucose metabolism or hypertension than in those without such abnormalities (-21.0% vs -8.4%, p < 0.01; -22.7% vs -9.5%, p < 0.05; and -22.5% vs -5.9%, p < 0.05; respectively).	Ezetimibe	39-48	component of oligomeric golgi complex 2	Homo sapiens	22-27	
20155988-9	2010	The reduction in LDL-C levels with ezetimibe monotherapy was also correlated with the number of metabolic abnormalities (rho = 0.426, p = 0.013).	Ezetimibe	35-44	component of oligomeric golgi complex 2	Homo sapiens	17-22	
20155988-10	2010	CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities.	Ezetimibe	18-27	component of oligomeric golgi complex 2	Homo sapiens	136-141	
20155988-10	2010	CONCLUSIONS: Both ezetimibe monotherapy and combination therapy with ezetimibe and a statin were able to safely and effectively control LDL-C levels in Japanese patients with dyslipidaemia, including those with metabolic abnormalities.	Ezetimibe	69-78	component of oligomeric golgi complex 2	Homo sapiens	136-141